Editorials

The Histopathological Classification of ANCA-associated Glomerulonephritis Comes of Age
A. Tanna, C.D. Pusey .............................................. 265

Composite Measures of Impact and Activity in Psoriatic Arthritis: A Conceptual Framework
W. Tillett ................................................................. 268

Review

Quality of Care for SLE: Mind the Knowledge Gap
V. Golder, E.F. Morand, A.Y. Hoi ................................. 271

Psoriatic Arthritis

The 12-item PsA Impact of Disease Questionnaire: Construct Validity, Reliability, and Interpretability in a Clinical Setting
M. Di Carlo, A. Becciolini, V. Lato, C. Crotti, E.G. Favalli, F. Salaffi .............................................. 279

The Risk of Developing Diabetes Mellitus in Patients with PsA: A Cohort Study
L. Eder, V. Chandran, R. Cook, D.D. Gladman .............................................. 286

Sjögren Syndrome

Detailed Analysis of the Articular Domain in Patients with Primary Sjögren Syndrome
R.V. Moerman, S. Arends, P.M. Meiners, et al. .............................................. 292

Vasculitis

Giant Cell Arteritis–related Stroke: A Retrospective Multicenter Case-control Study
H. de Boysson, E. Liozon, D. Lariviére, et al. .............................................. 297

Histopathological Classification and Renal Outcome in Patients with ANCA-associated Renal Vasculitis: A Study of 186 Patients and Metaanalysis
Y.X. Chen, J. Xu, X.X. Pan, et al. .............................................. 304

Incidence of Malignancy Prior to ANCA–associated Vasculitis Compared to the General Population
E.E. van Daalen, C. Rahmattulla, R. Wolterbeek, J.A. Bruijn, I.M. Bajema .............................................. 314

Myositis

Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis
S. Moghadam-Kia, C.V. Oddis, S. Sato, M. Kuwana, R. Aggarwal .............................................. 319

Pediatric Rheumatology

Clinical Orofacial Examination in JIA: International Consensus-based Recommendations for Monitoring Patients in Clinical Practice and Research Studies

Prevalence of Anti-infliximab Antibodies and Their Associated Co-factors in Children with Refractory Arthritis and/or Uveitis: A Retrospective Longitudinal Cohort Study
F.A. Aeschlimann, F. Angst, K.D. Hofer, et al. .............................................. 334

The Juvenile PsA Cohort in the CARRA Registry: Clinical Characteristics, Classification, and Outcomes

Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance
D.B. Horton, K.B. Onel, T. Beukelman, S. Ringold .............................................. 352

Sleep Disturbances and Neurobehavioral Performance in JIA

Gout

Predictors of Mortality in People with Recent-onset Gout: A Prospective Observational Study
Z.L. Vincent, G. Gamble, M. House, et al .............................................. 368

The Pharmacodynamics, Pharmacokinetics, and Safety of Albalofenate in Combination with Febuxostat When Treating Hyperuricemia Associated with Gout
A.S. Steinberg, B.D. Vince, Y.J. Choi, R.L. Martin, C.A. McWherter, P.F. Boudes .............................................. 374

Free online via JRheum Full Release option

Contents continued on page xvi
Sex-specific Relationship of Serum Uric Acid with All-cause Mortality in Adults with Normal Kidney Function: An Observational Study
E. Kang, S.S. Hwang, D.K. Kim, et al. ........................... 380

Serum Uric Acid and the Risk of Incident and Recurrent Gout: A Systematic Review
A. Shiozawa, S.M. Szabo, A. Bolzani, A. Cheung, H.K. Choi .............................................. 388

Correspondence
Association of Colchicine Price and Emergency Department Visits for Gout? M.E. Mullins ...................... 397
Reply S. Jinno .......................................................... 397

Letter
Increased Incidence of GI Side Effects in Patients Taking HCQ: A Brand-related Issue?
A. Srinivasa, S. Tosounidou, C. Gordon ...................... 398

Meetings in Rheumatology ................................. x